trial

An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCTId NCT00146523
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 247 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2006-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
247 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-05
Primary completion
2006-07
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Mifepristone

Sponsors

Corcept TherapeuticsLead Sponsor

Investigators

1
Katherine Beebe, PhDStudy Director

Sites

19 total
Sofia, BulgariaSofia, BulgariaSofia, BulgariaSofia, BulgariaVarna, BulgariaOsijek, CroatiaRijeka, CroatiaSplit, CroatiaZagreb, CroatiaZagreb, CroatiaZagreb, CroatiaBucharest, Romania

Linked catalysts

1
An International Study of the Safety and Tolerability of Corlux for Psychotic Sy — primary completion2006-07

Facts & assertions

4 sourced
Enrollment
247
Phase
PHASE3
Primary Completion Date
2006-07
Status
COMPLETED
relationships
The graph out of here
drug
Mifepristone
drug
lead_sponsor
Corcept Therapeutics
company
indication
Depression
indication
Major Depressive Disorder
indication
Depressive Disorder, Major
indication
investigator
Katherine Beebe, PhD
person